Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cinclus Pharma Holding ABFRA:J8P +2.30%2 Earnings Yield (Joel Greenblatt) % is -163.93% as of Jun. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 2/100. The stock has 4 warning signs investors should review. Among 1,011 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 98.12% on this metric.
Cinclus Pharma Holding AB's Enterprise Value for the quarter that ended in Jun. 2026 was €15.44 Mil.
Cinclus Pharma Holding AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-26.81 Mil. Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -163.93%.
The historical rank and industry rank for Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:J8P'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1591.35 Med: -64.35 Max: 1594.39
Current: -114.94
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Cinclus Pharma Holding AB was 1594.39%. The lowest was -1591.35%. And the median was -64.35%.
FRA:J8P's Earnings Yield (Joel Greenblatt) % is ranked worse than 98.12% of 1011
companies
in the Drug Manufacturers industry
Industry Median: 2.94
vs FRA:J8P: -114.94
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cinclus Pharma Holding AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Cinclus Pharma Holding AB Earnings Yield (Joel Greenblatt) % Related Terms
Cinclus Pharma Holding AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cinclus Pharma Holding AB Earnings Yield (Joel Greenblatt) % Chart
FRA:J8P vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) % falls into.
Cinclus Pharma Holding AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cinclus Pharma Holding ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Cinclus Pharma Holding AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.81 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -163.93% mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Earnings Yield (Joel Greenblatt) % of -163.93% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #992 out of 1011 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) % too high?
Cinclus Pharma Holding AB's current Earnings Yield (Joel Greenblatt) % is -163.93%. Based on the distribution chart, Cinclus Pharma Holding AB ranks #992 out of 1011 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #992 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 2.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 2.94, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current Earnings Yield (Joel Greenblatt) % is -163.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Earnings Yield (Joel Greenblatt) % of -163.93%. The current Earnings Yield (Joel Greenblatt) % is -163.93%. Cinclus Pharma Holding AB's overall GF Score™ is 2/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Earnings Yield (Joel Greenblatt) % is -163.93% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
2GF Score
Get the complete analysis for FRA:J8P
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
